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diagnostic test at the Bangladesh-India-Myanmar
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Background: The rapid diagnostic test (RDT) has been adopted in contemporary malaria control and management
programmes around the world as it represents a fast and apt alternative for malaria diagnosis in a resource-limited
setting. This study assessed the performance of a HRP-2/pLDH based RDT (ParascreenW Pan/Pf) in a laboratory setting
utilizing clinical samples obtained from the field.
Methods: Whole blood samples were obtained from febrile patients referred for malaria diagnosis by clinicians from
two different Upazila Health Complexes (UHCs) located near the Bangladesh-India and Bangladesh-Myanmar border
where malaria is endemic. RDT was performed on archived samples and sensitivity and specificity evaluated with expert
microscopy (EM) and quantitative PCR (qPCR).
Results: A total of 327 clinical samples were made available for the study, of which 153 were Plasmodium
falciparum-positive and 54 were Plasmodium vivax-positive. In comparison with EM, for P. falciparum malaria, the
RDT had sensitivity: 96.0% (95% CI, 91.2-98.3) and specificity: 98.2% (95% CI, 94.6-99.5) and for P. vivax, sensitivity: 90.7%
(95% CI, 78.9-96.5) and specificity: 98.9% (95% CI, 96.5-99.7). Comparison with qPCR showed, for P. falciparum malaria,
sensitivity: 95.4% (95% CI, 90.5-98.0) and specificity: 98.8% (95% CI, 95.4-99.7) and for P. vivax malaria, sensitivity: 89.0%
(95% CI,77.0-95.4) and specificity: 98.8% (95% CI, 96.5-99.7). Sensitivity varied according to different parasitaemia for
falciparum and vivax malaria diagnosis.
Conclusion: ParascreenW Pan/Pf Rapid test for malaria showed acceptable sensitivity and specificity in border belt
endemic areas of Bangladesh when compared with EM and qPCR.Background
Malaria is often lethal with high potential expenditure for
health if diagnosis is inaccurate [1]. Accurate diagnosis of
malaria is of increasing importance as the prevalence of
malaria is declining around the globe, making surveillance
and screening more important for programme manage-
ment [2,3] and to restrict the use of anti-malarial drugs to
restrain the spread of drug resistance [4].
For decades, expert microscopy (EM) of peripheral thick
and thin blood smears has been the standard diagnostic
test for malaria, however, it is time consuming and requires
substantial expertise [1,5]. Enzyme-linked immunosorbent
assay (ELISA) and polymerase chain reaction (PCR)-based* Correspondence: shafiul@icddrb.org
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reproduction in any medium, provided the ordiagnostic tests have been introduced which ameliorate
sensitivity and specificity of malaria diagnosis, but only in
reference settings where well equipped laboratory facilities
are available, making it difficult to implement in a field
setting [6]. Other nascent molecular methods, such as
loop-mediated isothermal amplification (LAMP) [7-9] and
real-time quantitative nucleic acid sequence-based ampli-
fication (QT-NASBA) [10] are in use, but the efficacy of
each is unproven.
After being introduced in the early 1990s, rapid diag-
nostic tests (RDTs) have become an attractive alternative
to the above-mentioned methods in a resource-limited
setting for malaria diagnostics. The antigen-based RDTs
detect specific antigens produced by malaria parasites
by reaction with bound antibodies on an absorbent
nitrocellulose membrane. Among several types of RDTs
the two-band tests and three-band tests are mostd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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species (Plasmodium falciparum), usually by detecting
histidine-rich protein 2 (HRP2), or detect any of the four
most common malaria parasites (P. falciparum, Plasmo-
dium vivax, Plasmodium malariae and Plasmodium
ovale), typically by detecting pan-Plasmodium-specific
lactate dehydrogenase (pLDH), while three-band tests
detect both the P. falciparum-specific antigen HRP2
and the pLDH or any one species specific LDH (mostly
P. vivax). The third band is the test control band
[1,5,11].
Southeast Bangladesh, northeast India and southwest
Myanmar are similar in geographical characteristics
and endemic for malaria. Plasmodium falciparum is the
most abundant parasite, followed by P. vivax in these
countries [6,11,12]. The presence of P. malariae and
P. ovale has also been reported in each country [13-16].
These three countries share their borders, making trans-
border malaria transmission plausible. The presence of all
four parasites in these mostly remote and resource-limited
areas illustrate the importance of a RDT that can detect
all malaria parasites. Amongst the locally available RDTs,
ParascreenW Pan/Pf Rapid test for malaria (Zephyr Bio-
medical Systems, India), hereafter noted as Parascreen, is
a RDT that has the capability to detect all types of human
malaria, as it detects P. falciparum-specific HRP-2 and
pan-Plasmodium-specific LDH. It has been evaluated
against microscopy and conventional PCR in field and
laboratory settings [12,17-24]. Here, the assessment of
Parascreen in a laboratory setting and its performance
compared with EM and qPCR are described.
Methods
Study area and population
Whole blood samples were obtained from febrile patients
with clinical symptoms referred for laboratory investiga-
tion between May 2009 to December 2010. The repre-
sented regions include Matiranga Upazila in Khagrachari
district and Ramu Upazila in Cox’s Bazar district, two dif-
ferent subdistricts of the southeastern part of Bangladesh
from corresponding UHC. Matiranga borders Tripura
state of India and Ramu borders Myanmar, where malaria
is endemic [15,16] and is caused mainly by P. falciparum
and P. vivax.
Sample collection
An expert medical technologist collected approximately
5 mL of blood from adult subjects and 3 mL from minor
subjects by venipuncture. Thick and thin blood films
were prepared in duplicate using two drops of blood
for each sample. The remaining blood was preserved
at −20°C in EDTA tube and transported to the Parasi-
tology Laboratory, icddr,b in cool boxes maintaining the
temperature below 4°C using ice bags.Approval from Research Review Committee (RRC) and
Ethical Review Committee (ERC) of icddr,b was obtained
for this study. Permission for conducting the study was
obtained from the National Malaria Control Programme
(NMCP). All participants or legal guardians signed in-
formed consent before participant enrolment and sample
collection. Complete anonymity was maintained at each
stage of the study.
Expert microscopy (EM)
Blood smears were stained with Giemsa and screened
for parasites under the (100X) oil immersion lens at the
field site by experienced microscopists in the correspon-
ding UHC. The microscopy results were confirmed by a
second independent, experienced microscopist who was
blinded to prior results. Parasite density was determined
by both microscopists counting the parasites and leuco-
cytes [25] and the average was used for the study. When
there was any disagreement in diagnosis by the two
microscopists for any sample and mixed (P. falciparum
and P. vivax) infection were excluded from the study.
Rapid diagnostic tests (RDTs)
Parascreen (Zephyr Biomedical Systems, India; Lot No
101159) is a three-band antigen detection RDT which
comes in cassette format. It employs a recombinant
antibody against pLDH to detect Plasmodium-specific
LDH and anti-HRP2 antibody to detect P. falciparum-
specific HRP2. All RDTs were performed on archived
blood samples by trained and skilled laboratory personnel
at the Parasitology Laboratory, icddr,b following the ma-
nufacturer’s instructions. Briefly, one pink-purple line in the
proximal area (control line) interprets negative for malaria;
one pink-purple line in the middle area, along with the
control line, interprets non-P. falciparum infection, ex-
clusively P. vivax in this study; one pink-purple line,
along with the previous two bands, interprets P. falciparum
infection. If any of the two test lines or control line did
not appear, the test was invalid and repeated.
DNA isolation
DNA was isolated using QIAamp DNA blood mini kit
(Qiagen Sciences Inc, USA) following the manufacturer’s
instructions from 200 μL of archived whole blood.
qPCR
Quantitative PCR (qPCR) was performed on isolated
DNA following the method described by Alam et al. [6]
with InvitrogenW SYBR Green I supermix UDG (Life
Technologies Corporation, USA). The sensitivity and
specificity of qPCR for P. falciparum was 97.1 and 97.6%,
respectively, while for P. vivax 95.2 and 98.1% [6]. Any
mixed (P. falciparum and P. vivax) infection diagnosed by
qPCR was not considered in this study.
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All data were encoded in an Excel data sheet and the
performance of RDT was calculated by means of the
following indicators: sensitivity, specificity, positive pre-
dictive value (PPV), negative predictive value (NPV) and
agreement (kappa) were calculated with their correspond-
ing 95% confidence intervals (95% CI), using EM and
qPCR as reference standards. Sensitivity was calculated
as the proportion of positive RDT test results among
malaria-positive samples identified by EM and qPCR,
while specificity was calculated as the proportion of
negative test results among the malaria-negative samples
identified by the reference standards. PPV and NPV
were obtained as the true positive results among all
malaria-positive samples and the true negative results
among all negative samples, respectively [26]. Agreement
(k) analysis was conducted in IBM SPSS Statistics, version
17.0 (IBM Corporation, NY, USA) by creating a 2 × 2
contingency table.
Results
In total, 327 febrile patients were included in this study
from two UHCs. The results of EM, qPCR and Para-
screen are provided in Table 1. With EM, there were
207 (63.3%) positive malaria cases, of which 153 (73.9%)
were P. falciparum infection and 54 (26.0%) were P.
vivax infection. The parasite density for P. falciparum
ranged between 16 and 261,480 parasites/μL (IQR:
7,500-50,100) with median value of 19,960 parasites/μL,
while the parasite density for P. vivax ranged between
16 and 25,120 parasites/μL (IQR: 320–4,800) with me-
dian value of 1,140 parasites/μL. qPCR confirmed 208
(63.6%) positive malaria cases, of which 154 (74.0%)
were P. falciparum and 54 (25.9%) were P. vivax. With
Parascreen, there were 202 (61.7%) malaria positive
cases, of which 150 (74.2%) were P. falciparum and 52
(25.7%) were P. vivax infection.
Table 2 represents the calculated indicators when
Parascreen was compared with EM and qPCR. EM being
the reference standard, Parascreen had the following
results, for any kind of malaria detection, sensitivity: 97.1%
(95% CI, 93.5-98.8) and specificity: 99.1% (95% CI, 96.8-
99.9); for P. falciparum malaria detection, sensitivity:
96.0% (95% CI, 91.2-98.3) and specificity: 98.2% (95% CI,Table 1 Parascreen® diagnosis results and comparison




Negative Pf Pv Negative Pf Pv
Negative 125 119 3 3 119 3 3
Pf 150 1 147 2 0 148 2
Pv 52 0 3 49 0 3 49
Total 327 120 153 54 119 154 5494.6-99.5) and for P. vivax malaria detection, sensitivity:
90.7% (95% CI, 78.9-96.5) and specificity: 98.9% (95% CI,
96.5-99.7). When qPCR was used as the reference stand-
ard, Parascreen had the following results for any kind of
malaria detection, sensitivity: 97.1% (95% CI, 93.5-98.8)
and specificity: 100% (96.1-100.0); for P. falciparum
malaria detection, sensitivity: 95.4% (95% CI, 90.5-98.0)
and specificity: 98.8% (95% CI, 95.4-99.7) and for P. vivax
malaria detection, sensitivity: 89.0% (95% CI, 77.0-95.4)
and specificity: 98.8% (95% CI, 96.5-99.7).
Parascreen showed higher sensitivity (93.3-100%) in
detecting samples with parasite densities >500 parasites/
μL for both P. falciparum and P. vivax, whereas for
parasite densities ranging from 1–500 parasites/μL, the
sensitivity was low (60.0%-83.3%) (Figure 1).
Discussion
Parascreen showed acceptable performance in this study
with overall sensitivity and specificity of 97.1 and 99.1%,
respectively, when compared to EM, and 97.1 and 100%,
respectively, in comparison with qPCR. Parascreen can
detect all types of non-falciparum malaria but in this
study only P. vivax was considered as P. malariae and
P. ovale cases were not present in the study samples
[13,14]. Parascreen demonstrated varying sensitivity and
specificity when compared with EM and qPCR depending
on parasite species (P. falciparum and P. vivax) and para-
sitaemia of infections.
Several evaluation studies of Parascreen in different
countries reported overall sensitivity ranging from 47.5
to 95.5% and specificity from 64.3 to 98.5% with varying
performance for falciparum and non-falciparum malaria
detection [12,17-21,23,24]. Parascreen has been evaluated by
WHO RDT evaluation programme and for P. falciparum
detection it showed almost 100% detection rates while
for P. vivax it was approximately 30% [27]. Here, in this
study, for P. falciparum detection, the sensitivity and
specificity was also in concordance with the previous
findings [12,20,21], while for P. vivax detection, improved
sensitivity and specificity are reported. The improved
sensitivity and specificity of P. vivax detection compared
to previous findings may be due to the increased re-
lease of antigen through parasite lysis in the archived
sample [1] or due to the improvement in the product.
This finding is also corroborated by a meta analysis
where mean sensitivity and specificity of 95.0 and
95.2%, respectively, for HRP-2 based assays and 93.2
and 98.5%, respectively, for pLDH based assays were
calculated [28].
In a study in India, Parascreen showed 94.0% sensitivity
and 72.0% specificity for P. falciparum and for P. vivax
77.2% sensitivity and 98.1% specificity were recorded when
compared with EM and similar values observed when
compared with PCR [12].
Table 2 Comparative indicators of ParascreenW, when using EM and qPCR as reference standard
Reference
standard
Test Results by Parascreen
Sensitivity [%(95% CI)] Specificity [%(95% CI)] PPV [%(95% CI)] NPV [%(95% CI)] Agreement (k)
EM
Overall 97.1 (93.5-98.8) 99.1 (94.7-99.9) 99.5 (96.8-99.9) 95.2 (89.4-98.0) 0.954
Pf 96.0 (91.2-98.3) 98.2 (94.6-99.5) 98.0 (93.8-99.4) 96.6 (92.4-98.6) 0.945
Pv 90.7 (78.9-96.5) 98.9 (96.5-99.7) 94.2 (83.0-98.4) 98.1 (95.5-99.3) 0.910
qPCR
Overall 97.1 (93.5-98.8) 100.0 (96.1-100.0) 100.0 (97.6-100.0) 95.2 (89.4-98.0) 0.961
Pf 95.4 (90.5-98.0) 98.8 (95.4-99.7) 98.6 (94.7-99.7) 96.0 (94.7-99.7) 0.945
Pv 89.0 (77.0-95.4) 98.8 (96.5-99.7) 94.2 (83.0-98.4) 97.8 (95.0-99.1) 0.899
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erties have been evaluated in field settings [11,26]. The
SD 05FK60 RDT evaluated in the Rakhaine state of
Myanmar showed 90.2% sensitivity and 98.5% specificity
for P. falciparum and 79.4% sensitivity and 98.7% specifi-
city for non-falciparum malaria [11]. The VIKIA Malaria
Ag Pf/Pan™ test showed 98.0 and 100% sensitivity for
P. falciparum and non-falciparum malaria, respectively,
with specificity of 98.0 and 100%, respectively [26].
Onsite (Pf/Pan), a RDT with similar detection principle
recently evaluated in Bangladesh, reported 94.2% sensi-
tivity and 99.5% specificity for falciparum malaria detec-
tion and for vivax malaria detection it showed sensitivity
and specificity of 97.3 and 98.7%, respectively [5] which















Figure 1 Varied sensitivity of ParascreenW (Pf/pan) according to diffeWHO recommends sensitivity ≥95% at ≥100 parasites/uL
for RDTs [1]. In this study, for both falciparum and vivax
malaria detection, sensitivity was less than the recom-
mended values for low parasitaemia; however, conside-
ring fewer low parasitaemia samples, statistically valid
conclusions have not been attained.
In this study, Parascreen was unable to detect three
microscopically confirmed falciparum malaria samples
with parasitaemia ranging from 112 to 2,600 parasites/
uL. This might be caused by the degradation of HRP-2
target antigen as the study was carried out with archived
samples. Intraspecies sequence variation [29], deletions
or mutations of HRP-2 gene [30,31] among different P.
falciparum isolates could also account for false negative
tests. The extent of HRP-2 variations in Bangladesh is
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well as some African countries [30,32]. In this study,
three P. falciparum samples showed no HRP-2 test line
but Pan specific test line, thus considered as P. vivax, as
other types of malaria were absent in the study samples.
The intraspecies variation, mutation or deletions in the
HRP-2 gene can cause non-expression of HRP-2 [30]
which may explain this. Parascreen identified three P.
vivax-positive samples with parasitaemia ranging from
16 to 200 parasites/uL as negative. This might be due to
low pLDH level, as pLDH level is directly proportional
to parasitaemia [33]. In many studies, a reduced sensitiv-
ity for non-falciparum malaria detection, compared to
falciparum detection, in combined HRP-2/pLDH RDTs
has also been reported [5,6,11,26].
As all four malarial parasites co-exist in the Bangladesh-
India-Myanmar border area, an important criterion for
selection of an appropriate RDT is the capability to
detect all types of malaria. It is advantageous to use
Pf/Pan RDTs which can do so. The high predictive
values for Parascreen indicate that it is able to detect
true malaria cases as well as ruling out non-malaria
cases. High sensitivity, specificity and predictive values
for Parascreen present it as a viable alternative for ma-
laria diagnostics in Bangladesh-India-Myanmar border
areas where malaria is endemic.
The absence of P. malariae and P. ovale samples in this
study restricts the findings to the detection performance of
falcipaum and vivax malaria. The inclusion of P. malariae
and P. ovale in the study samples is needed to assess
non-falciparum malaria detection performance.
Conclusion
Parascreen showed acceptable performance for falciparum
as well as vivax malaria diagnosis in standard experimental
conditions. It can be employed in resource-limited settings
to diagnose all types of human malaria.
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